CANbridge Pharmaceuticals’ Licensing Agreement in China with GC Pharma

Ropes & Gray advised biopharmaceutical firm CANbridge Pharmaceuticals Inc. on the deal

CANbridge Pharmaceuticals Inc. closed an exclusive licensing agreement in China with GC Pharma, a South Korea-based company and one of the world’s largest protein products manufacturers, to commercialize Hunterase, a human recombinant iduronate-2 –sulfatase enzyme replacement therapy for the treatment of Hunter syndrome. The deal was announced on Jan 7.

Developed by GC Pharma, Hunterase is marketed in more than ten countries. There is no approved treatment for rare disease Hunter syndrome in China, unlike in some other nations.

The Ropes & Gray team included IP transactions partner Geoffrey Lin (Picture), IP transactions counsel David Chen (both of Shanghai), IP transactions partner Mark Bellomy (Boston), and life sciences partner Katherine Wang (Shanghai).

Involved fees earner: Mark Bellomy – Ropes & Gray; David Chen – Ropes & Gray; Geoffrey Lin – Ropes & Gray; Katherine Wang – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: CANbridge Pharmaceuticals;

Print Friendly, PDF & Email

Author: Michael Patrini